Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gamal Zaki

Internal Medicine Rochester Hills, MI Medical Doctor

NPI 1780674218 CMS profile 217039

2708 S Rochester Rd, Rochester Hills, MI 48307

Open in the dashboard

General payments

$11,620

507 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gamal Zaki of Rochester Hills, MI is reported in the CMS Open Payments database as having received $11,620 across 507 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,194 52
2024 General $1,399 67
2023 General $1,215 65
2022 General $1,441 79
2021 General $1,721 82
2020 General $1,561 59
2019 General $3,090 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gamal Zaki
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gamal Zaki were reported at $1,194. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gamal Zaki Internal Medicine median Middle half National median
2019 $3,090 $159 $48–$570 $163
2020 $1,561 $119 $33–$402 $114
2021 $1,721 $135 $37–$521 $132
2022 $1,441 $141 $42–$496 $149
2023 $1,215 $149 $45–$519 $160
2024 $1,399 $154 $47–$537 $164
2025 $1,194 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,428 42 payments
  2. Lilly USA, LLC $1,172 51 payments
  3. Novo Nordisk Inc $865 51 payments
  4. GlaxoSmithKline, LLC. $814 38 payments
  5. AbbVie, Inc. $670 40 payments
  6. Astellas Pharma US Inc $538 25 payments
  7. Sanofi-Aventis U.S. LLC $479 10 payments
  8. Pfizer Inc. $456 21 payments
  9. Merck Sharp & Dohme Corporation $431 24 payments
  10. Allergan Inc. $403 13 payments
  11. Other $4,363 192 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,431 505 payments
  2. Education $189 2 payments
Products named General payments · program years 2019–2025
  1. Prolia $753 30 payments
  2. EVENITY $654 29 payments
  3. TRULICITY $509 29 payments
  4. Ozempic $506 34 payments
  5. RYBELSUS $486 32 payments
  6. UBRELVY $413 23 payments
  7. NEXLETOL $396 18 payments
  8. MOUNJARO $388 14 payments
  9. TRELEGY ELLIPTA $387 18 payments
  10. MYRBETRIQ $378 20 payments
  11. Other $9,503 437 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 114 drugs

Part D claims

6,206

Median for Internal Medicine: 777

Drug cost

$547,242

Median for Internal Medicine: $73,373

Branded share of claims

18.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 77 $119,664
Eliquis Apixaban Brand 111 $99,349
Ozempic Semaglutide Brand 33 $52,639
Entresto Sacubitril/Valsartan Brand 37 $36,646
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 30 $32,158
Xarelto Rivaroxaban Brand 29 $30,117
Januvia Sitagliptin Phosphate Brand 24 $21,584
Linzess Linaclotide Brand 11 $16,704
Mounjaro Tirzepatide Brand 17 $15,957
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 63 $12,491

The 10 drugs with the highest cost, of 114 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$92,546

Medicare's payments for the services billed

Medicare patients

223

Average age 78

Services billed

1,287

105 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 36%
Ischemic heart disease 33%
Depression 26%
Atrial fibrillation 23%
Chronic kidney disease 22%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $143
$143 — —
SHINGRIX
  • GlaxoSmithKline, LLC. $142
$142 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $136
$136 — —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $76
$76 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $51
  • Lilly USA, LLC $23
$74 77 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

507 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record